Can you take Iptacopan with Nilotinib?

Nilotinib has a moderate potential interaction with Cardiovascular Conditions and Disorders.

Cardiovascular events (including arterial vascular occlusive events, peripheral arterial occlusive disease, and ischemic cerebrovascular events) have been reported in patients receiving BCR-ABL tyrosine kinase inhibitors. Patients should seek immediate medical attention if acute signs or symptoms of cardiovascular events occur. Cardiovascular status should be evaluated, and cardiovascular risk factors should be monitored and actively managed during treatment.

Nilotinib has a moderate potential interaction with Electrolyte Abnormalities.

Nilotinib can cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia. Electrolyte abnormalities should be corrected prior to initiating nilotinib and during therapy; these electrolytes should be monitored periodically during therapy.

Iptacopan has a moderate potential interaction with Hemodialysis.

No clinically significant differences in the exposure of iptacopan were observed between patients with estimated GFR in the range of 25 to less than 90 mL/min compared to those with normal estimated GFR. No data are available in patients on dialysis.

Nilotinib has a major potential interaction with Hypokalemia.

The use of nilotinib is contraindicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome. Nilotinib prolongs the QT interval in a concentration-dependent manner; QT prolongation may lead to torsade de pointes, which can result in syncope, seizures, and/or death. Before initiating nilotinib and periodically, electrolyte, calcium, and magnesium blood levels should be tested. Hypokalemia or hypomagnesemia must be corrected before starting treatment and these electrolytes should be monitored periodically. ECGs should be obtained at baseline, 7 days after starting nilotinib, following dose adjustments, and periodically as clinically indicated.

Iptacopan has a major potential interaction with Infection.

Initiation of therapy with iptacopan is contraindicated in patients with unresolved serious infection caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae type B. Complete or update vaccination against encapsulated bacteria at least 2 weeks before the first dose of iptacopan, according to current Advisory Committee on Immunization Practices (ACIP) recommendations for patients on complement inhibitors. Antibacterial drug prophylaxis is recommended for patients who require urgent iptacopan therapy but are not up to date with vaccines against encapsulated bacteria according to ACIP recommendations; such patients should receive these vaccines as soon as possible. Interruption of iptacopan should be considered in patients who are undergoing treatment for serious infections.

Nilotinib has a moderate potential interaction with Intestinal Anastomoses.

Nilotinib exposure is reduced in patients with total gastrectomy. More frequent monitoring of these patients is recommended; a dose increase or alternative therapy should be considered.

Nilotinib has a moderate potential interaction with Lactose Intolerance.

Nilotinib capsule formulations contain lactose and are not recommended for patients with rare hereditary problems of galactose intolerance, severe lactase deficiency with a severe degree of intolerance to lactose-containing products, or glucose-galactose malabsorption.

Iptacopan has a moderate potential interaction with Liver Disease.

The use of iptacopan is not recommended in patients with severe liver dysfunction (Child-Pugh C). No dose adjustment is needed for patients with mild or moderate liver dysfunction (Child-Pugh A or B).

Nilotinib has a moderate potential interaction with Liver Disease.

Nilotinib exposure is increased in patients with hepatic impairment. If possible, alternative therapies should be considered; if nilotinib use is necessary, the dosage should be reduced and the QT interval should be monitored closely. Nilotinib may cause hepatotoxicity as measured by elevations in bilirubin, AST, ALT, and alkaline phosphatase; liver function tests should be monitored monthly or as clinically indicated and after dosage adjustments.

Nilotinib has a major potential interaction with Long QT Syndrome.

The use of nilotinib is contraindicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome. Nilotinib prolongs the QT interval in a concentration-dependent manner; QT prolongation may lead to torsade de pointes, which can result in syncope, seizures, and/or death. Before initiating nilotinib and periodically, electrolyte, calcium, and magnesium blood levels should be tested. Hypokalemia or hypomagnesemia must be corrected before starting treatment and these electrolytes should be monitored periodically. ECGs should be obtained at baseline, 7 days after starting nilotinib, following dose adjustments, and periodically as clinically indicated.

Nilotinib has a major potential interaction with Magnesium Imbalance.

The use of nilotinib is contraindicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome. Nilotinib prolongs the QT interval in a concentration-dependent manner; QT prolongation may lead to torsade de pointes, which can result in syncope, seizures, and/or death. Before initiating nilotinib and periodically, electrolyte, calcium, and magnesium blood levels should be tested. Hypokalemia or hypomagnesemia must be corrected before starting treatment and these electrolytes should be monitored periodically. ECGs should be obtained at baseline, 7 days after starting nilotinib, following dose adjustments, and periodically as clinically indicated.

Nilotinib has a moderate potential interaction with Pancreatitis.

Nilotinib can increase serum lipase. Patients with a history of pancreatitis may be at greater risk of elevated serum lipase. Serum lipase should be monitored monthly or as clinically indicated. If lipase elevations occur with abdominal symptoms, treatment should be interrupted and appropriate diagnostic evaluation should be considered to exclude pancreatitis.

Iptacopan has a moderate potential interaction with Peritoneal dialysis.

No clinically significant differences in the exposure of iptacopan were observed between patients with estimated GFR in the range of 25 to less than 90 mL/min compared to those with normal estimated GFR. No data are available in patients on dialysis.